RoosterBio Revenue and Competitors

Frederick, MD USA

Location

$28.2M

Total Funding

3D

Industry

Estimated Revenue & Valuation

  • RoosterBio's estimated annual revenue is currently $8.4M per year.(i)
  • RoosterBio's estimated revenue per employee is $147,900
  • RoosterBio's total funding is $28.2M.

Employee Data

  • RoosterBio has 57 Employees.(i)
  • RoosterBio grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$189.2M82513%$197.2MN/A
#2
$8.4M578%$28.2MN/A
Add Company

RoosterBio (www.RoosterBio.com) is a Maryland-based biotechnology company founded in 2012 and focused on the simplification of translating Cell Therapy and Tissue Engineering technologies into the clinic and onto the market. Regenerative Medicine is showing great promise in the clinic, but the cost, availability, and standardization of the cellular materials from which researchers can perform experiments and clinical trials is holding the field back. RoosterBio is designing products to help to quicken the pace of research and development to help build a robust and sustainable Regenerative Medicine industry which will lead to more rapid and wide-spread implementation of life saving therapies. Furthermore, the field of Synthetic Biology is providing a framework from which to begin designing standardized biological components, and we are very interested in marrying the fields of Cell and Tissue Engineering with Synthetic Biology in order to further our cause. Our team are experienced leaders in stem cell research, tissue engineering, cell therapy bioprocessing, therapeutic product development, and cell manufacturing operations. We hope to help advance the field of Regenerative Medicine as well as the broader fields of cell-based products and devices by providing robust, high-quality, affordable (cellular) raw materials from which to perform product development experiments. We aim to share the knowledge we have gained over the years with our customers and the greater scientific community as a part of these efforts. In this way we believe that we can make our own little “dent in the universe”, and help to accelerate the development of what we are calling the “Cell-based BioEconomy”.

keywords:Biotechnology, Medical Devices, Synthetic Biology

$28.2M

Total Funding

57

Number of Employees

$8.4M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RoosterBio News

2022-04-06 - Cell and Gene Therapy Pioneer Robert Preti Joins RoosterBio Board of Directors

FREDERICK, Md., April 4, 2022 /PRNewswire-PRWeb/ -- RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cell and exosome...

2021-10-05 - RoosterBio Names Life Science Industry Leader, Timothy M. Kelly, Ph.D., as New Chief Executive Officer

"What sets Tim apart is his deep technical knowledge in cell and gene therapy technologies and the specialized manufacturing needs required by these unique therapies.” - Jon A. Rowley, PhD, founder and chief product officer, RoosterBio FREDERICK, Md. (PRWEB) October 05, 2021 RoosterBio, Inc., ...

2021-05-20 - RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium

RoosterGEM™ Built with cGMP-compatible processes, RoosterGEM represents a breakthrough in practical transduction efficiency. - Jon Rowley, Founder and Chief Product Officer of RoosterBio FREDERICK, Md. (PRWEB) May 20, 2021 RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal c ...

2021-03-11 - RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants

We are very pleased to support hMSC-based methods and applications in Genetic Engineering by enabling a rapid and efficient path to generate key cellular raw materials and scale up manufacturing, leading to shortened timelines on research and clinical translation. - RoosterBio CEO Margot Connor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.2M57-5%N/A
#2
$5.1M5719%N/A
#3
$7.6M5814%N/A
#4
$18.4M5841%N/A
#5
$15.1M582%N/A